Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients
“Steroids were the biggest predictor of why certain immunotherapies may not be effective” – Dr. Fumito Ito
The Effect of GLP-1 Receptor Agonists on Outcomes in Metastatic Renal Cell Carcinoma Patients Undergoing Immune Checkpoint Inhibitor Therapy
GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint inhibitors in 994-patient analysis.
Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial
Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast cancer: 24-month rates 94.7% vs 90.2% placebo (HR 0.56, p<0.0001).
Efficacy and Safety of Dordaviprone (ONC201) in Prospective Clinical Trials of Adult and Pediatric Recurrent H3 K27M-Mutant Diffuse Glioma Patients
Dordaviprone shows 16.7% response rate in adults with recurrent H3 K27M gliomas, with durable responses lasting median 15.1 months.
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab perioperatively extends survival in resectable locally advanced HNSCC with PD-L1 CPS ≥1 – first checkpoint inhibitor approval.
How Low Do You Need to Go? Association Between Various PSA Response Measures and Clinical Outcomes in mCSPC in the Veteran Health Administration (VHA) Data
PSA nadir <0.2 ng/mL within 9 months shows 54% lower death risk vs 22% for ≥90% decline in mCSPC veterans receiving ADT-based therapy.
The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice
MT-sDNA screening showed 0.2% CRC detection rate and 73% false-positive rate, raising questions about effectiveness in average-risk patients.
The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice Read More »
CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC
Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients with resectable NSCLC.
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-Grade Non–Muscle-Invasive Bladder Cancer
XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection safety.
Cell Painting Identifies Flavonoids That Are Toxic to Bladder Cancer Cells
Researchers identified six plant-derived flavonoids toxic to bladder cancer cells using innovative Cell Painting microscopy technology.
Cell Painting Identifies Flavonoids That Are Toxic to Bladder Cancer Cells Read More »